Living-donor kidney transplantation for atypical haemolytic uremic syndrome with pre-emptive eculizumab use

Transplant International

Volumn 28, Issue 3, 2015, Pages 366-369

  Parikova, Alena ^a   Fronek, Jiri P ^a   Viklicky, Ondrej ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

atypical haemolytic uremic syndrome; complement system; eculizumab; living donor kidney transplantation

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; COMPLEMENT ACTIVATION; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LETTER; LIVING DONOR; MALE; PRIORITY JOURNAL; REMISSION; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GRAFT REJECTION; PREOPERATIVE CARE; PROCEDURES;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; PREOPERATIVE CARE;

EID: 84925374743     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12440     Document Type: Letter

References (5)

1. Westra D, Volokhina E, Heijden E, et al,. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 2010; 25: 2195.
2. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C,. New insights into postrenal transplant haemolytic uremic syndrome. Nat Rev Nephrol 2011; 7: 23.
3. Nürnberger J, Philipp T, Witzke O, et al,. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542.
4. Zuber J, Le Quintrec M, Morris H, Fremaux-Bacchi V, Loirat C, Legendre C,. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev 2013; 27: 117.
5. Kim AH, Dimitriou ID, Holland MC, et al,. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol 2004; 173: 2524.